Cartala · 20MG

Cartalax is a synthetic tetrapeptide bioregulator consisting of the sequence Ala-Glu-Asp-Leu (AEDL), developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Belonging to the same "Khavinson cytomedin" class as Epithalon (AEDG, pineal), Cortagen (AEDP, cortex), and Pancreagen (KEDW, pancreatic), Cartalax is the tetrapeptide identified by Khavinson and colleagues as the cartilage / connective tissue peptide bioregulator. The compound is proposed to function through tissue-specific gene expression modulation in chondrocyte and connective tissue cell populations. Cartalax has been investigated in the Russian academic literature (Bulletin of Experimental Biology and Medicine; Khavinson and colleagues) for chondrocyte gene expression, extracellular matrix biology, and age-associated cartilage cell function in preclinical research models. Like other Khavinson short-peptide bioregulators, Cartalax is studied primarily as a research tool for tissue-specific short-peptide pharmacology rather than as a defined receptor agonist.

Benefits (Research Focus)

• Chondrocyte gene expression research — studied for short-peptide bioregulator effects on cartilage cell populations

• Extracellular matrix biology — investigated for collagen and proteoglycan gene expression in connective tissue research models

• Khavinson SAR research — explored alongside other Khavinson short-peptide bioregulators for structure-activity studies

• Tissue-specific peptide signaling — examined as a "cytomedin" class compound for tissue-selective gene expression research

• Age-associated cartilage research — researched for chondrocyte biology endpoints in aged tissue research models

What Researchers Look At

• Chondrocyte gene expression panels (COL2A1, ACAN, SOX9) in cartilage cell research

• Type II collagen and proteoglycan synthesis markers in extracellular matrix research

• Comparative pharmacology versus other Khavinson short-peptide bioregulators

• Tetrapeptide stability and structure-activity relationships in cartilage cell research models

• Aged-tissue versus young-tissue model responses in comparative chondrocyte research

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 20 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Cartalax

• Synonyms: AEDL peptide; Ala-Glu-Asp-Leu tetrapeptide; Khavinson cartilage peptide bioregulator

• Class: Synthetic tetrapeptide; Khavinson bioregulator / cytomedin class; cartilage tissue-targeted

• Sequence: Ala-Glu-Asp-Leu (AEDL) — 4 amino acids

• Origin: Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology (Russia)

• Formula / M.W.: C₁₈H₃₀N₄O₉, ~430.45 g/mol (verify against batch COA)

• CAS: Not formally assigned in mainstream chemical databases (peptide bioregulator class)

⚠️ Disclaimer

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Cartalax VPeptide Canada — January 12, 2026

• Cartalax VPeptide — May 4, 2026